GlassScriptPhysician profile
Steven Medvid
NPI 1356399398
$515.99
in general payments reported to CMS, 2019-2025
12 companies · $193 in 2025
The $193 reported for 2025 was more than what 75% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.78 · 2020: $27.93 · 2022: $47.29 · 2023: $120 · 2024: $29.39 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $67.57 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.44 | 2024-2025 | Lifevest |
| Amgen INC. | $66.77 | 2022-2023 | Repatha |
| Astellas Pharma US INC | $59.14 | 2019-2020 | |
| Pfizer INC. | $50.02 | 2023-2025 | |
| Stryker Corporation | $40.24 | 2025 | Flowtriever |
| Gilead Sciences, INC. | $34.35 | 2023 | Veklury |
| Alexion Pharmaceuticals, INC. | $31.77 | 2025 | Ultomiris |
| Cvrx, INC. | $31.74 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $26.88 | 2025 | Uptravi |
| Merck Sharp & Dohme LLC | $24.63 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Abbvie INC. | $15.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Medvid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.